Oncology Clinical Trials in Bethesda, MD
As of June 2026, 221 paid clinical trials are recruiting for Oncology in Bethesda, Maryland. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
221 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
About research studies in Bethesda
Bethesda has approximately 932 recruiting research studies across a wide range of therapeutic areas. Maryland hosts Johns Hopkins Medicine and the NIH Clinical Center in Bethesda, giving participants access to some of the most advanced early-phase research in the country.
Top Research Study Locations in Bethesda
Researchers run research studies in Bethesda, MD at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| National Institutes of Health Clinical Center | Healthy Volunteers, Healthy Volunteer, Obesity | 658 |
| Walter Reed National Military Medical Center | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy | 75 |
| National Cancer Institute Developmental Therapeutics Clinic | Metastatic Malignant Solid Neoplasm, Advanced Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | 12 |
| Suburban Hospital | Asthma, Atherosclerosis, Atrial Fibrillation | 10 |
| Mid-Atlantic Epilepsy and Sleep Center | Developmental and Epileptic Encephalopathy, Dravet Syndrome, Focal Epilepsy | 9 |
| National Cancer Institute | Non Small Cell Lung Cancer, Prostate Cancer, Advanced Solid Tumor | 7 |
| National Institutes of Health | Abdominal Neoplasm, Advanced Solid Tumors, Anaplastic Astrocytoma | 7 |
| National Institute of Health | Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma (DLBCL) | 6 |
| The Center for Cancer and Blood Disorders | Acute Myeloid Leukaemia (AML), Advanced Melanoma, Advanced Non-small Cell Lung Cancer | 6 |
| American Oncology Partners of Maryland, PA | Chronic Lymphocytic Leukemia, Immune Thrombocytopenic Purpura (ITP), Leukemia, B-cell | 5 |
| Uniformed Services University of the Health Sciences | Alcohol Use, Arrythmia, Cardiovascular Diseases | 5 |
| NIH Clinical Center | Age-Related Macular Degeneration, COVID-19, Long Haul, Chronic Granulomatous Disease | 4 |
| National Cancer Institute (NCI) | Melanoma, Breast Cancer, Cardiofaciocutaneous Syndrome | 4 |
| American Oncology Partners of Maryland Pa | Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, B-cell Malignancy | 3 |
| American Oncology Partners, PA | Breast Neoplasms, Chronic Lymphocytic Leukemia, Multiple Myeloma Refractory | 3 |
| Maryland Oncology Hematology, P.A. | Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) | 3 |
| Mid Atlantic Epilepsy and Sleep Ctr | Generalized Myasthenia Gravis, Secondary Progressive Multiple Sclerosis (SPMS) | 3 |
| NCI - Center for Cancer Research | Recurrent Hairy Cell Leukemia, Hairy Cell Leukemia, Hereditary Leiomyomatosis and Renal Cell Carcinoma | 3 |
| National Institutes of Health (NIH) | Eosinophilic Colitis, Eosinophilic Esophagitis, Eosinophilic Gastritis | 3 |
| Praxis Research Site | Focal Seizure, Epilepsy, Tonic-Clonic, Focal Onset Seizure | 3 |
| Center for Cancer and Blood Disorders-American Oncology Partners of Maryland | Follicular Lymphoma (FL), Multiple Myeloma, Chronic Lymphocytic Leukemia | 3 |
| American Oncology Partners of Maryland | Advanced Cancer, Metastatic Non Small Cell Lung Cancer | 2 |
| Center for Cancer and Blood Disorders | Multiple Myeloma, Sickle Cell Disease | 2 |
| GSK Investigational Site | Colonic Neoplasms, Multiple Myeloma, Neoplasms, Colon | 2 |
| NIH Clinical Site | Drug Induced Liver Injury, Liver Diseases | 2 |
Active & Upcoming Studies in Bethesda (2026)
Recruiting trials in Bethesda grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (257 active studies)
- Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases · National Cancer Institute (NCI)
- A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer · Phase 1 · University of Wisconsin, Madison
Neurology & pain (60 active studies)
- Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD · National Institute of Neurological Disorders and Stroke (NINDS)
- Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain · Phase 1, Phase 2 · National Institute of Neurological Disorders and Stroke (NINDS)
Diabetes & metabolic (26 active studies)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Effects of Meal Macronutrients on Postprandial Lipids · Phase 2 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Vaccines (22 active studies)
- BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI) · National Institute on Deafness and Other Communication Disorders (NIDCD)
Mental health & behavior (19 active studies)
- Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI) · National Institute on Deafness and Other Communication Disorders (NIDCD)
- INSIGHT: Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention · Uniformed Services University of the Health Sciences
Cardiovascular (19 active studies)
- NHLBI-Emory Advanced Cardiac CT Reconstruction · National Heart, Lung, and Blood Institute (NHLBI)
- Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging · Phase 3 · National Heart, Lung, and Blood Institute (NHLBI)
HIV / STI (17 active studies)
- Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B · Phase 2 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pediatric (10 active studies)
- NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors · National Cancer Institute (NCI)
- A Repository to Study Host-Microbiome Interactions in Health and Disease · National Institute of Allergy and Infectious Diseases (NIAID)
Eye & vision (5 active studies)
- Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants · Phase 4 · Neurotech Pharmaceuticals
- Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 · National Eye Institute (NEI)
Common conditions studied in Bethesda
- Healthy Volunteers (22 active studies). Healthy-volunteer studies examine how new drugs behave in the body, helping researchers understand safety and dosing before later-phase trials.
- Prostate Cancer (21 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Breast Cancer (19 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Healthy Volunteer (17 active studies). Healthy-volunteer studies examine how new drugs behave in the body, helping researchers understand safety and dosing before later-phase trials.
- Obesity (16 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Neoplasms (13 active studies). Recruiting Neoplasms studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Bethesda
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Local regulations and guidelines
Clinical trials in Maryland are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Maryland research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Bethesda. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Bethesda
Hipa.ai aggregates every recruiting study in Bethesda from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Bethesda?
There are approximately 932 recruiting clinical trials in Bethesda, Maryland listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Bethesda pay participants?
Most recruiting trials in Bethesda compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Bethesda?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Bethesda?
The most common conditions under active study in Bethesda include Healthy Volunteers (22), Prostate Cancer (21), Breast Cancer (19), Healthy Volunteer (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Bethesda?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Bethesda on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Bethesda?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Bethesda?
Recruiting research sites in Bethesda include National Institutes of Health Clinical Center, Walter Reed National Military Medical Center, National Cancer Institute Developmental Therapeutics Clinic, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Bethesda right now?
The largest active categories in Bethesda are Cancer & tumors (257), Neurology & pain (60), Diabetes & metabolic (26). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.